EP2338900B1
(en)
|
2001-11-13 |
2014-01-01 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
|
AU2002360291A1
(en)
|
2001-12-17 |
2003-06-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
DK2292779T3
(en)
*
|
2003-09-30 |
2017-02-27 |
Univ Pennsylvania |
ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
|
WO2006078279A2
(en)
|
2004-04-28 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
WO2006033672A2
(en)
|
2004-04-28 |
2006-03-30 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
CN106906241B
(zh)
|
2005-04-07 |
2020-09-11 |
宾夕法尼亚大学托管会 |
增强腺相关病毒载体功能的方法
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
CA2649182C
(en)
|
2006-04-07 |
2018-01-02 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
WO2007127264A2
(en)
|
2006-04-28 |
2007-11-08 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for aav
|
EP2016174A2
(en)
*
|
2006-04-28 |
2009-01-21 |
The Trustees of the University of Pennsylvania |
Modified aav vectors having reduced capsid immunogenicity and use thereof
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
PL2191001T3
(pl)
|
2007-04-09 |
2017-01-31 |
University Of Florida Research Foundation, Inc. |
Kompozycje wektora RAAV mające białka kapsydu zmodyfikowane tyrozyną i sposoby ich zastosowania
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
US20090215879A1
(en)
*
|
2008-02-26 |
2009-08-27 |
University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
EP2425000B1
(en)
*
|
2009-04-30 |
2019-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
US9133479B2
(en)
*
|
2009-06-03 |
2015-09-15 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
AU2011238708B2
(en)
|
2010-03-29 |
2016-02-11 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically Induced Transgene Ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
JP5963743B2
(ja)
|
2010-04-23 |
2016-08-03 |
ユニバーシティ オブ マサチューセッツ |
Cnsターゲティングaavベクターおよびその使用方法
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US10738326B2
(en)
|
2010-10-27 |
2020-08-11 |
Jichi Medical University |
Adeno-associated virus vector for gene transfer to nervous system cells
|
US9409953B2
(en)
*
|
2011-02-10 |
2016-08-09 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
JP6224459B2
(ja)
|
2011-02-17 |
2017-11-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異性を改変し、aav9媒介遺伝子導入を改善するための組成物および方法
|
EP3699286A1
(en)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
EP2699680B1
(en)
|
2011-04-21 |
2017-12-27 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
WO2012145601A2
(en)
|
2011-04-22 |
2012-10-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
EP3147295B2
(en)
*
|
2011-08-24 |
2023-11-22 |
The Board of Trustees of the Leland Stanford Junior University |
New avv capsid proteins for nucleic acid transfer
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
WO2013082268A1
(en)
|
2011-11-30 |
2013-06-06 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
US9611305B2
(en)
|
2012-01-06 |
2017-04-04 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
US20130280170A1
(en)
|
2012-04-20 |
2013-10-24 |
Aladar A. Szalay |
Imaging methods for oncolytic virus therapy
|
JP6385920B2
(ja)
*
|
2012-05-09 |
2018-09-05 |
オレゴン ヘルス アンド サイエンス ユニバーシティー |
アデノ随伴ウイルスプラスミド及びベクター
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
AU2013287281B2
(en)
|
2012-07-11 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated gene therapy for RPGR x-linked retinal degeneration
|
EP3415167B1
(en)
|
2012-08-01 |
2024-05-29 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
CA2885544A1
(en)
*
|
2012-09-28 |
2014-04-03 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
WO2014055960A1
(en)
|
2012-10-05 |
2014-04-10 |
Genelux Corporation |
Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
AU2014244167A1
(en)
*
|
2013-03-13 |
2015-10-08 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
JP6628285B2
(ja)
|
2013-03-14 |
2020-01-08 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
Als関連ジアミノ酸リピート含有タンパク質
|
DK2984166T3
(da)
|
2013-03-15 |
2020-07-20 |
Univ Pennsylvania |
Sammensætninger til behandling af mpsi
|
AU2014227766B2
(en)
*
|
2013-03-15 |
2018-10-04 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding AAV vectors
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
EP3003391B1
(en)
*
|
2013-05-31 |
2021-09-22 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
EP3561062A1
(en)
|
2013-09-13 |
2019-10-30 |
California Institute of Technology |
Selective recovery
|
JP6985795B2
(ja)
|
2013-09-26 |
2021-12-22 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
標的遺伝子治療のための合成コンビナトリアルaavカプシドライブラリー
|
CN106029107A
(zh)
*
|
2013-10-07 |
2016-10-12 |
基罗米克有限责任公司 |
使用疾病特异性启动子治疗心血管疾病的组合物和方法
|
DK3459965T3
(da)
|
2013-10-11 |
2021-02-22 |
Massachusetts Eye & Ear Infirmary |
Fremgangsmåder til forudsigelse af forfædrevirussekvenser og anvendelser deraf
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
WO2015138357A2
(en)
|
2014-03-09 |
2015-09-17 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of otc deficency
|
MX2016011585A
(es)
|
2014-03-10 |
2016-11-29 |
Uniqure Ip Bv |
Vectores aav mejorados adicionales producidos en celulas de insecto.
|
SG11201607738WA
(en)
|
2014-03-17 |
2016-10-28 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression in cone cells
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
CA2946392A1
(en)
|
2014-04-25 |
2015-10-29 |
James M. Wilson |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
MX365658B
(es)
|
2014-05-13 |
2019-06-10 |
Univ Pennsylvania |
Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
BR112017005892A2
(pt)
|
2014-09-24 |
2017-12-12 |
Hope City |
variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
JP7023108B2
(ja)
|
2014-10-21 |
2022-02-21 |
ユニバーシティ オブ マサチューセッツ |
組み換えaavバリアントおよびその使用
|
US10335466B2
(en)
|
2014-11-05 |
2019-07-02 |
Voyager Therapeutics, Inc. |
AADC polynucleotides for the treatment of parkinson's disease
|
WO2016073739A1
(en)
*
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
CN112410339A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
JP2017535266A
(ja)
|
2014-11-14 |
2017-11-30 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)を治療する組成物および方法
|
EP4344741A2
(en)
*
|
2014-11-21 |
2024-04-03 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to the central nervous system
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
AU2015364636B9
(en)
|
2014-12-16 |
2021-12-02 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for Juvenile Batten Disease
|
EP3242945B1
(en)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
WO2016115543A2
(en)
|
2015-01-16 |
2016-07-21 |
University Of Washington |
Novel micro-dystrophins and related methods of use
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
BR112017018846A2
(pt)
|
2015-03-02 |
2018-07-31 |
Adverum Biotechnologies, Inc. |
composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
|
IL282053B2
(en)
|
2015-03-10 |
2023-03-01 |
Univ Columbia |
Constructions of glut1-linked recombinant aav vectors, preparations and kits containing them and their use
|
US10883117B2
(en)
|
2015-03-24 |
2021-01-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
EP3285780A4
(en)
|
2015-04-24 |
2018-12-19 |
University of Massachusetts |
Modified aav constructions and uses thereof
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
EP3291765A4
(en)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
METHODS OF DELIVERING AN AGENT TO THE EYE
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
CA2985786A1
(en)
*
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
AU2016275909A1
(en)
|
2015-05-13 |
2017-11-09 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated expression of anti-influenza antibodies and methods of use thereof
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
US10509045B2
(en)
|
2015-05-29 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Methods for diagnosing Huntington's disease
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
|
DK3872085T3
(da)
|
2015-07-30 |
2023-04-03 |
Massachusetts Eye & Ear Infirmary |
Stam-virussekvenser og anvendelser heraf
|
GB2595063B
(en)
|
2015-07-31 |
2022-03-09 |
Univ Minnesota |
Modified cells and methods of therapy
|
CN108368521A
(zh)
|
2015-08-06 |
2018-08-03 |
宾夕法尼亚州大学信托人 |
Glp-1和其在用于治疗代谢疾病的组合物中的用途
|
ES2929110T3
(es)
|
2015-08-25 |
2022-11-24 |
Univ Duke |
Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN
|
EP3344650A4
(en)
|
2015-08-31 |
2019-04-17 |
The Trustees Of The University Of Pennsylvania |
AAV-EPO FOR THE TREATMENT OF PETS
|
IL296929A
(en)
|
2015-09-24 |
2022-12-01 |
Univ Pennsylvania |
A preparation and method for the treatment of a complement-mediated disease
|
IL292830B2
(en)
|
2015-09-28 |
2023-06-01 |
Univ Florida |
Methods and compositions for stealth virus antibody vectors
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
WO2017066764A2
(en)
*
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
US20200181644A1
(en)
*
|
2015-10-22 |
2020-06-11 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial aav3 capsid library
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
WO2017075119A1
(en)
|
2015-10-28 |
2017-05-04 |
The Trustees Of The Univeresity Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
BR112018007453A2
(pt)
|
2015-11-05 |
2018-10-23 |
Bamboo Therapeutics Inc |
genes modificados de ataxia de friedreich e vetores para a terapia gênica
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
KR102423442B1
(ko)
*
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
EP3387118B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
EP3984550A1
(en)
|
2015-12-11 |
2022-04-20 |
Massachusetts Eye & Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
ES2921450T3
(es)
|
2015-12-11 |
2022-08-25 |
Univ Pennsylvania |
Terapia génica para el tratamiento de la hipercolesterolemia familiar
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
EP3394270A1
(en)
*
|
2015-12-14 |
2018-10-31 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated viral vectors useful in treatment of spinal muscular atropy
|
WO2017106345A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
RU2762747C2
(ru)
|
2015-12-14 |
2021-12-22 |
Зе Трастис Оф Зе Юниверсити Оф Пенсильвания |
Генная терапия офтальмологических нарушений
|
WO2017136536A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
KR20180121899A
(ko)
|
2016-02-03 |
2018-11-09 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
I형 점액다당류증을 치료하기 위한 유전자 요법
|
HRP20231451T1
(hr)
|
2016-02-05 |
2024-03-01 |
Emory University |
Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF EXPRESSION OF GRAINHEAD PROTEIN
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
KR20230125339A
(ko)
|
2016-04-15 |
2023-08-29 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
IL310729A
(en)
|
2016-04-15 |
2024-04-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins that are variants of CD80 and their uses
|
CA3019426A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
CN109562191A
(zh)
|
2016-04-15 |
2019-04-02 |
宾夕法尼亚州大学信托人 |
用于治疗血友病a的基因疗法
|
AU2017250358B2
(en)
|
2016-04-15 |
2023-06-01 |
Alpine Immune Sciences, Inc. |
ICOS ligand variant immunomodulatory proteins and uses thereof
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
SG10202009852PA
(en)
*
|
2016-04-15 |
2020-11-27 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017192699A1
(en)
*
|
2016-05-03 |
2017-11-09 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
CR20180589A
(es)
|
2016-05-13 |
2019-02-27 |
4D Molecular Therapeutics Inc |
Cápsulas variantes de virus adenoasociados y métodos de uso de estas
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
JP7220080B2
(ja)
|
2016-05-18 |
2023-02-09 |
ボイジャー セラピューティクス インコーポレイテッド |
ハンチントン病治療組成物及び方法
|
RU2764919C2
(ru)
|
2016-06-13 |
2022-01-24 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Оптимизированные гены и экспрессионные кассеты cln1, и их применение
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
EP3481958A4
(en)
|
2016-07-08 |
2019-12-25 |
The Trustees of The University of Pennsylvania |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF RDH12-RELATED DISORDERS AND DISEASES
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
KR20230161535A
(ko)
*
|
2016-07-26 |
2023-11-27 |
바이오마린 파머수티컬 인크. |
신규 아데노-관련 바이러스 캡시드 단백질
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
EP3827812A1
(en)
|
2016-07-29 |
2021-06-02 |
The Regents of the University of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
CA3040483A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
WO2018075978A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
US20180245065A1
(en)
|
2016-11-01 |
2018-08-30 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
JP7229161B2
(ja)
|
2016-12-30 |
2023-02-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
フェニルケトン尿症を処置するための遺伝子療法
|
CN110290814A
(zh)
|
2016-12-30 |
2019-09-27 |
宾夕法尼亚州立大学托管会 |
用于治疗威尔逊病的基因疗法
|
EP3570895A1
(en)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
JP2020506705A
(ja)
|
2017-02-01 |
2020-03-05 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
シトルリン血症を処置するための遺伝子療法
|
CN110546265A
(zh)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞及其组合物和方法
|
EP3595688A4
(en)
|
2017-02-20 |
2020-12-30 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY TO TREAT FAMILY HYPERCHOLESTERINEMIA
|
JP7237843B2
(ja)
|
2017-02-21 |
2023-03-13 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
修飾されたaavキャプシドタンパク質およびその使用
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
CA3052487A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Influenza vaccines based on aav vectors
|
US11827906B2
(en)
*
|
2017-02-28 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clade f vector and uses therefor
|
EP3589738A4
(en)
|
2017-03-01 |
2021-01-06 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR EYE DISORDERS
|
US11376321B2
(en)
|
2017-03-02 |
2022-07-05 |
Genethon |
Method for removing anti-AAV antibodies from a blood-derived composition
|
JP7386083B2
(ja)
|
2017-03-16 |
2023-11-24 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Cd80バリアント免疫調節タンパク質及びその使用
|
PL3596116T3
(pl)
|
2017-03-16 |
2024-05-13 |
Alpine Immune Sciences, Inc. |
Białka immunomodulujące wariant Pd-l1 i ich zastosowania
|
WO2018170023A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
SG11201908384XA
(en)
|
2017-03-24 |
2019-10-30 |
Lankenau Inst Medical Res |
Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
|
SG11201909136PA
(en)
|
2017-03-31 |
2019-10-30 |
Staidson Beijing Biopharmaceuticals Co Ltd |
Shrna expression cassette, polynucleotide sequence carrying the same, and use thereof
|
WO2018189208A1
(en)
|
2017-04-10 |
2018-10-18 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
WO2018191666A1
(en)
|
2017-04-14 |
2018-10-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
CA3060250A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Florida Research Foundation, Incorporated |
Regulation of ran protein translation by pkr and eif2a-p pathways
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
SG11201909870SA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
AU2018261003A1
(en)
|
2017-05-05 |
2019-11-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's Disease
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
AU2018265414B2
(en)
|
2017-05-10 |
2022-01-20 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
|
RU2019139555A
(ru)
|
2017-05-11 |
2021-06-11 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия нейрональных цероидных липофусцинозов
|
CA3098592A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
BR112020000063A2
(pt)
|
2017-07-06 |
2020-07-14 |
The Trustees Of The University Of Pennsylvania |
terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
|
US11596698B2
(en)
|
2017-07-07 |
2023-03-07 |
Genethon |
Synthetic polynucleotides encoding a human FKRP protein
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
AU2018307877A1
(en)
|
2017-07-27 |
2020-01-02 |
Novartis Ag |
Sheddase resistant TREM2 variants
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
CR20200165A
(es)
|
2017-09-20 |
2020-06-05 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociados y métodos de uso de estas
|
CN118006607A
(zh)
|
2017-09-22 |
2024-05-10 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
AU2018335752A1
(en)
|
2017-09-22 |
2020-03-12 |
Christian HINDERER |
Gene therapy for treating Mucopolysaccharidosis type ii
|
CA3076214A1
(en)
|
2017-09-26 |
2019-04-04 |
University Of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
EP4124658A3
(en)
|
2017-10-16 |
2023-04-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
WO2019079496A2
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
|
CA3078517A1
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
JP7420710B2
(ja)
|
2017-10-20 |
2024-01-23 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
組換えaav9由来ベクターの治療有効量の網膜下送達を含む、対象の錐体視細胞において目的のポリヌクレオチドを発現させる方法
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
CA3083761A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iiib
|
MX2020005663A
(es)
|
2017-11-30 |
2020-08-20 |
Univ Pennsylvania |
Terapia genica para mucopolisacaridosis iii a.
|
US20210071149A1
(en)
|
2017-12-19 |
2021-03-11 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
KR20200110376A
(ko)
|
2018-01-17 |
2020-09-23 |
아드레나스 테라퓨틱스, 인코포레이티드 |
21-하이드록실라제 결핍을 위한 아데노-관련 바이러스 유전자 요법
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
CA3091806A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
KR20210006327A
(ko)
*
|
2018-02-27 |
2021-01-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
|
JP7304878B2
(ja)
*
|
2018-03-16 |
2023-07-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
キャプシド改変による組織特異的遺伝子送達の増加
|
CA3094311A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
KR20210015770A
(ko)
|
2018-04-05 |
2021-02-10 |
제네똥 |
감소된 간 향성을 갖는 AAV9과 AAVrh74의 하이브리드 재조합 아데노-관련 바이러스 세로타입
|
CA3098566A1
(en)
|
2018-04-29 |
2019-11-07 |
Zhuchun WU |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
WO2019212921A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Scalable clarification process for recombinant aav production
|
IL278393B2
(en)
|
2018-05-08 |
2023-11-01 |
Univ Rutgers |
AAV compatible polymerization proteins bind to laminin
|
JP2021522811A
(ja)
|
2018-05-09 |
2021-09-02 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
フェニルケトン尿症の治療方法
|
CN112368391A
(zh)
|
2018-05-11 |
2021-02-12 |
马萨诸塞眼科耳科诊所 |
腺相关病毒的肝脏特异性嗜性
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
EP3793616A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CN112533621A
(zh)
|
2018-06-04 |
2021-03-19 |
卡利迪生物治疗有限公司 |
强化病毒疗法的基于细胞的媒介
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
CN112469822A
(zh)
|
2018-06-14 |
2021-03-09 |
再生生物股份有限公司 |
用于重组aav生产的阴离子交换色谱
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
JP2021533757A
(ja)
|
2018-08-10 |
2021-12-09 |
リジェネクスバイオ インコーポレイテッド |
組換えaav生成のためのスケーラブルな方法
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
SG11202102058UA
(en)
|
2018-08-30 |
2021-03-30 |
Tenaya Therapeutics Inc |
Cardiac cell reprogramming with myocardin and ascl1
|
JP2022502046A
(ja)
|
2018-09-26 |
2022-01-11 |
カリフォルニア インスティテュート オブ テクノロジー |
標的遺伝子療法のためのアデノ随伴ウイルス組成物
|
US20210395776A1
(en)
|
2018-09-28 |
2021-12-23 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
JP7289033B2
(ja)
|
2018-10-01 |
2023-06-09 |
徹 宮崎 |
神経変性疾患治療剤
|
BR112021006060A2
(pt)
|
2018-10-01 |
2021-07-20 |
The Trustees Of The University Of Pennsylvania |
composições úteis para tratamento de gangliosidose gm1
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
US20210324483A1
(en)
|
2018-10-15 |
2021-10-21 |
Regenxbio Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス/Sf9システムにおけるrAAVの大規模産生のための発現ベクター
|
JP2022513376A
(ja)
|
2018-10-22 |
2022-02-07 |
ユニバーシティ オブ ロチェスター |
レトロウイルスインテグラーゼ-Cas9融合タンパク質を使用した指向性非相同DNA挿入によるゲノム編集
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
AU2019377141B2
(en)
|
2018-11-06 |
2024-06-06 |
Calidi Biotherapeutics (Nevada), Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
SG11202105030VA
(en)
|
2018-11-16 |
2021-06-29 |
Astellas Pharma Inc |
Method for treating muscular dystrophy by targeting utrophin gene
|
KR20210123289A
(ko)
|
2018-11-21 |
2021-10-13 |
인답타 세라뷰틱스 인코포레이티드 |
자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법
|
KR20210135987A
(ko)
|
2018-11-30 |
2021-11-16 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd86 변이체 면역조절 단백질 및 그의 용도
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
MX2021008135A
(es)
|
2019-01-04 |
2021-08-11 |
Ultragenyx Pharmaceutical Inc |
Construcciones de terapia genica para el tratamiento de la enfermedad de wilson.
|
WO2020150287A1
(en)
|
2019-01-14 |
2020-07-23 |
University Of Rochester |
Targeted nuclear rna cleavage and polyadenylation with crispr-cas
|
WO2020150556A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
KR20210130158A
(ko)
|
2019-01-31 |
2021-10-29 |
오레곤 헬스 앤드 사이언스 유니버시티 |
Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
|
WO2020172490A1
(en)
|
2019-02-22 |
2020-08-27 |
The Trustees Of The University Of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Biettiクリスタリン網膜症を治療するための組成物及び方法
|
US20220154210A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
CN114040980A
(zh)
|
2019-02-26 |
2022-02-11 |
宾夕法尼亚州大学信托人 |
可用于治疗克拉伯病的组合物
|
SG11202108459QA
(en)
|
2019-02-27 |
2021-09-29 |
Actym Therapeutics Inc |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
WO2020193636A1
(en)
|
2019-03-25 |
2020-10-01 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
KR20220004987A
(ko)
|
2019-04-03 |
2022-01-12 |
리젠엑스바이오 인크. |
눈 병리에 대한 유전자 요법
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
FI3953483T3
(fi)
|
2019-04-11 |
2023-11-30 |
Regenxbio Inc |
Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
|
CN113993552A
(zh)
|
2019-04-19 |
2022-01-28 |
再生生物股份有限公司 |
腺相关病毒载体制剂和方法
|
US20220195462A1
(en)
|
2019-04-24 |
2022-06-23 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
MX2021013266A
(es)
*
|
2019-04-29 |
2021-11-17 |
Univ Pennsylvania |
Nuevas capsides de aav y composiciones que las contienen.
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
WO2020232044A1
(en)
|
2019-05-14 |
2020-11-19 |
Biomarin Pharmaceutical Inc. |
Methods of redosing gene therapy vectors
|
TW202111122A
(zh)
|
2019-05-28 |
2021-03-16 |
日商安斯泰來製藥股份有限公司 |
藉靶向dmpk基因治療肌肉萎縮症之方法
|
CN114207120A
(zh)
|
2019-05-30 |
2022-03-18 |
坚固生物科技公司 |
重组疱疹病毒载体
|
WO2020261178A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
KR20220069917A
(ko)
|
2019-07-02 |
2022-05-27 |
엠6피 테라퓨틱스 (스위처랜드) 엘엘씨 |
리소좀 축적 장애의 치료를 위한 벡터 조성물 및 이의 사용 방법
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
WO2021005210A1
(en)
|
2019-07-11 |
2021-01-14 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated virus
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
EP4004206A1
(en)
|
2019-07-23 |
2022-06-01 |
University of Rochester |
Targeted rna cleavage with crispr-cas
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
US20220396806A1
(en)
|
2019-07-26 |
2022-12-15 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
CN114364802A
(zh)
|
2019-08-16 |
2022-04-15 |
摩大力斯医疗株式会社 |
通过靶向lama1基因来治疗肌营养不良症的方法
|
WO2021034920A1
(en)
*
|
2019-08-20 |
2021-02-25 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
CA3149401A1
(en)
|
2019-08-26 |
2021-03-04 |
Stephen Joseph Pakola |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
AU2020346062A1
(en)
|
2019-09-13 |
2022-03-24 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CN114521143A
(zh)
|
2019-09-19 |
2022-05-20 |
吉尼松公司 |
减轻fkrp心脏毒性的基因治疗表达系统
|
EP4038194A1
(en)
|
2019-10-04 |
2022-08-10 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
AU2020362119A1
(en)
|
2019-10-07 |
2022-05-26 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
WO2021072129A2
(en)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
CN115003820A
(zh)
|
2019-10-08 |
2022-09-02 |
爱科霍拉有限公司 |
用于眼部治疗的组合物和方法
|
CA3157700A1
(en)
|
2019-10-17 |
2021-04-22 |
Stridebio, Inc. |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
WO2021092298A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
MX2022006427A
(es)
|
2019-11-28 |
2022-09-07 |
Regenxbio Inc |
"construcciones para terapia génica con microdistrofina y uso de las mismas.
|
EP4073257A1
(en)
|
2019-12-09 |
2022-10-19 |
UCL Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
KR20220112283A
(ko)
|
2019-12-10 |
2022-08-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
Hunter 질환 치료용 아데노-연합된 바이러스 벡터
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
US20230059395A1
(en)
|
2020-01-22 |
2023-02-23 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
JP2023512043A
(ja)
|
2020-01-29 |
2023-03-23 |
レジェンクスバイオ インコーポレーテッド |
ムコ多糖症ivaの治療
|
KR20220148162A
(ko)
|
2020-01-29 |
2022-11-04 |
리젠엑스바이오 인크. |
인간 신경 또는 신경아교 세포에 의해 생성된 재조합 인간 이두로네이트-2-설파타아제 (ids)를 사용한 점액다당류증 ii의 치료
|
AU2021213826A1
(en)
|
2020-02-02 |
2022-09-01 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating GM1 gangliosidosis
|
US20230078498A1
(en)
|
2020-02-07 |
2023-03-16 |
University Of Rochester |
Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
|
JP2023514149A
(ja)
|
2020-02-07 |
2023-04-05 |
ユニバーシティ オブ ロチェスター |
リボザイムにより媒介されるrnaアセンブリ及び発現
|
IL294781A
(en)
|
2020-02-14 |
2022-09-01 |
Ultragenyx Pharmaceutical Inc |
Gene therapy for the treatment of cdkl5-deficient disorder
|
US20230136699A1
(en)
|
2020-02-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
BR112022017551A2
(pt)
|
2020-03-02 |
2022-11-16 |
Tenaya Therapeutics Inc |
Controle de vetor genético por micrornas expressos por cardiomiócito
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
KR20220153604A
(ko)
|
2020-03-11 |
2022-11-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
가공된 바이러스 입자를 사용하는 유전자 전달을 위한 방법 및 조성물
|
EP4121544A1
(en)
|
2020-03-19 |
2023-01-25 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
KR20220160069A
(ko)
|
2020-03-27 |
2022-12-05 |
유씨비 바이오파마 에스알엘 |
자율적 노브 도메인 펩티드
|
WO2021195519A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
JP2023519344A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
CRISPR-Cas13 crRNAアレイ
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
EP4126910A1
(en)
|
2020-04-01 |
2023-02-08 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
TW202204383A
(zh)
|
2020-04-10 |
2022-02-01 |
美商碩拿生物科學有限責任公司 |
用於治療蛋白質聚集病症之組合物及方法
|
KR20230020394A
(ko)
|
2020-04-15 |
2023-02-10 |
보이저 테라퓨틱스, 인크. |
Tau 결합 화합물
|
AU2021258194A1
(en)
|
2020-04-22 |
2022-11-24 |
Indapta Therapeutics, Inc. |
Natural killer (NK) cell compositions and methods for generating same
|
JP2023524414A
(ja)
|
2020-04-28 |
2023-06-12 |
ソラ・バイオサイエンシズ・エルエルシー |
Tdp-43プロテイノパチーの処置のための組成物および方法
|
KR20230029616A
(ko)
*
|
2020-05-05 |
2023-03-03 |
듀크 유니버시티 |
종간 호환가능한 아데노-관련 바이러스 조성물 및 이의 사용 방법
|
TW202208622A
(zh)
|
2020-05-12 |
2022-03-01 |
賓州大學委員會 |
用於治療克拉培氏病之組成物
|
IL298138A
(en)
|
2020-05-12 |
2023-01-01 |
Univ Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
AR122079A1
(es)
|
2020-05-13 |
2022-08-10 |
Akouos Inc |
Composiciones y métodos para tratar la perdida auditiva asociada a kcnq4
|
KR20230022175A
(ko)
|
2020-05-13 |
2023-02-14 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드의 향성 방향변경
|
AR122078A1
(es)
|
2020-05-13 |
2022-08-10 |
Akouos Inc |
Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
CN116096737A
(zh)
|
2020-06-05 |
2023-05-09 |
索拉生物科学有限公司 |
用于治疗突触核蛋白病的组合物和方法
|
MX2022016528A
(es)
|
2020-06-17 |
2023-06-02 |
Univ Pennsylvania |
Composiciones y métodos para el tratamiento de pacientes de terapia génica.
|
WO2021255245A2
(en)
|
2020-06-19 |
2021-12-23 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
CN115885043A
(zh)
*
|
2020-07-07 |
2023-03-31 |
德克萨斯大学系统董事会 |
用于dwarf开放阅读框的腺相关病毒载体
|
WO2022008711A1
(en)
|
2020-07-10 |
2022-01-13 |
Genethon |
A novel muscle-specific promoter
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
EP4179097A1
(en)
|
2020-07-13 |
2023-05-17 |
The Trustees of The University of Pennsylvania |
Compositions useful for treatment of charcot-marie-tooth disease
|
EP4182455A1
(en)
|
2020-07-15 |
2023-05-24 |
University of Rochester |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
AU2021315876A1
(en)
|
2020-07-27 |
2023-02-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
CN115927398A
(zh)
*
|
2020-07-29 |
2023-04-07 |
舒泰神(北京)生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
CA3192052A1
(en)
|
2020-08-17 |
2022-02-24 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
JP2023543125A
(ja)
|
2020-08-24 |
2023-10-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Glp-1受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
|
CN116887867A
(zh)
|
2020-08-26 |
2023-10-13 |
宾夕法尼亚州大学信托人 |
用于治疗grn相关成人发作性神经退行性病变的重组腺相关病毒
|
BR112023003972A2
(pt)
|
2020-09-04 |
2023-04-18 |
Univ Kobe Nat Univ Corp |
Complexos de um módulo de reconhecimento de sequência de ácido nucleico ligado a uma desaminase e de um fragmento amino-terminal de um módulo de reconhecimento de sequência de ácido nucleico, uma desaminase e um fragmento carboxi-terminal de um módulo de reconhecimento de sequência de ácido nucleico ligado ao mesmo, ácido nucleico, vetor, e, método para alterar um sítio alvo de um ácido desoxirribonucleico de fita dupla de uma célula
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
CA3197342A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
JP2023544797A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
脈絡膜上投与用の、高粘度製剤などの製剤
|
WO2022076711A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
TW202228646A
(zh)
|
2020-10-07 |
2022-08-01 |
美商銳進科斯生物股份有限公司 |
諸如凝膠調配物之用於脈絡膜上投與之調配物
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
AU2021358964A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
US20230365955A1
(en)
|
2020-10-09 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
AR123838A1
(es)
|
2020-10-18 |
2023-01-18 |
Univ Pennsylvania |
Vector mejorado de virus adenoasociado (aav) y usos de este
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
WO2022094461A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
EP4240861A1
(en)
|
2020-11-03 |
2023-09-13 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
IL303239A
(en)
|
2020-12-01 |
2023-07-01 |
Univ Pennsylvania |
Compositions and their uses for the treatment of Engelmann syndrome
|
KR20230117179A
(ko)
|
2020-12-01 |
2023-08-07 |
아카우오스, 인크. |
청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
WO2022133051A1
(en)
|
2020-12-16 |
2022-06-23 |
Regenxbio Inc. |
Method of producing a recombinant adeno-associated virus particle
|
JP2024503234A
(ja)
|
2020-12-23 |
2024-01-25 |
ファイザー・インク |
親和性クロマトグラフィーによるaavベクターの精製方法
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
EP4271419A1
(en)
|
2020-12-29 |
2023-11-08 |
Akouos, Inc. |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
KR20230133314A
(ko)
|
2021-01-21 |
2023-09-19 |
리젠엑스바이오 인크. |
재조합 폴리펩티드 및 바이러스의 개선된 생산
|
EP4281551A1
(en)
*
|
2021-01-25 |
2023-11-29 |
Trames Bio, Inc. |
Adeno-associated virus capsids and engineered ligand-gated ion channels for treating focal epilepsy and neuropathic pain
|
MX2023008826A
(es)
|
2021-02-01 |
2023-09-15 |
Regenxbio Inc |
Terapia génica para lipofuscinosis neuronal ceroidea.
|
EP4288553A1
(en)
*
|
2021-02-02 |
2023-12-13 |
University of Massachusetts |
Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
|
US20240093189A1
(en)
|
2021-02-05 |
2024-03-21 |
Maze Therapeutics, Inc. |
Vectors comprising stuffer polynucleotide sequences
|
CA3210955A1
(en)
*
|
2021-02-09 |
2022-08-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
KR20230145386A
(ko)
|
2021-02-10 |
2023-10-17 |
리젠엑스바이오 인크. |
재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료
|
MX2023009978A
(es)
|
2021-02-26 |
2023-09-06 |
Takeda Pharmaceuticals Co |
Composicion y metodos para el tratamiento de la enfermedad de fabry.
|
TW202246516A
(zh)
|
2021-03-03 |
2022-12-01 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2022198038A1
(en)
|
2021-03-19 |
2022-09-22 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
US20240191251A1
(en)
|
2021-04-05 |
2024-06-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
IL307633A
(en)
|
2021-04-12 |
2023-12-01 |
Univ Pennsylvania |
Useful preparations in the treatment of spinal muscular atrophy (SBMA)
|
EP4326753A2
(en)
|
2021-04-23 |
2024-02-28 |
University of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
AU2022262771A1
(en)
|
2021-04-23 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
EP4329820A1
(en)
|
2021-04-26 |
2024-03-06 |
Alexion Pharma International Operations Limited |
Adeno-associated viral vector capsids with improved tissue tropism
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
EP4334454A2
(en)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Novel aav vectors and methods and uses thereof
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
JP2024520815A
(ja)
*
|
2021-06-08 |
2024-05-24 |
エヌエフ2 セラピューティクス, インコーポレイテッド |
神経線維腫性障害を処置するための組成物および方法
|
JP2024522230A
(ja)
*
|
2021-06-18 |
2024-06-11 |
ダイノ セラピューティクス インコーポレイテッド |
カプシドバリアント及びそれを使用する方法
|
EP4359547A1
(en)
|
2021-06-22 |
2024-05-01 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
WO2022272056A2
(en)
*
|
2021-06-24 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
EP4367251A1
(en)
|
2021-07-08 |
2024-05-15 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
CA3226452A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
WO2023004407A2
(en)
*
|
2021-07-23 |
2023-01-26 |
Duke University |
Adeno-associated virus compositions and methods of use thereof
|
CN117794561A
(zh)
|
2021-07-30 |
2024-03-29 |
宫崎彻 |
缺血性疾病的治疗剂
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
KR20240073006A
(ko)
|
2021-08-11 |
2024-05-24 |
사나 바이오테크놀로지, 인크. |
동종이계 세포 요법을 위한 유전자 변형된 1차 세포
|
WO2023028567A2
(en)
*
|
2021-08-25 |
2023-03-02 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease
|
CA3229998A1
(en)
*
|
2021-08-25 |
2023-03-02 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
JP7175044B1
(ja)
|
2021-09-24 |
2022-11-18 |
株式会社中山事務所 |
波力発電装置
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
AU2022366947A1
(en)
|
2021-10-12 |
2024-05-02 |
Bridgebio Gene Therapy Llc |
Methods and compositions for treating leukodystrophies
|
AU2022368907A1
(en)
|
2021-10-20 |
2024-05-02 |
University Of Copenhagen |
Rejuvenation treatment of age-related white matter loss
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
IL311861A
(en)
|
2021-11-02 |
2024-06-01 |
Voyager Therapeutics Inc |
Adeno-associated virus capsid variants and their uses
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023091948A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
WO2023114901A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
TW202340467A
(zh)
|
2022-01-10 |
2023-10-16 |
賓州大學委員會 |
有用於治療c9orf72介導之病症之組成物及方法
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023135316A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
Gene therapy composition and treatment for dystrophin-related cardiomyopathy
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
AR128422A1
(es)
|
2022-02-02 |
2024-05-08 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023230409A1
(en)
*
|
2022-05-24 |
2023-11-30 |
Kate Therapeutics, Inc. |
Compositions for treating xlmtm
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
WO2024130067A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|